TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Delveinsight
KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight

The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.

Insights
EADSY   positive

Continued market leadership with higher deliveries, stronger profitability, and consistent production targets


LLY   positive

Developing promising second-generation KRAS G12C inhibitor olomorasib, with FDA Breakthrough Therapy designation and ongoing Phase III clinical trials